Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

Photo: Deal to progress Alzheimers vaccine

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

More on the subject:
Read all latest stories

Related articles

Photo

News • Urine-based diagnostics

New prostate cancer test to help avoid unnecessary biopsies

US researchers have developed and validated a new urine-based test for prostate cancer, which was shown to meaningfully reduce unnecessary prostate biopsies while providing highly accurate detection.

Photo

News • Presented at ESCMID Global

Immunoassay analyzer extends menu with new hepatitis assays

Beckman Coulter Diagnostics announced ahead of the ESCMID Global congress (formerly ECCMID) that it has extended the menu of DxI 9000 Immunoassay Analyzer* assays.

Photo

News • Research on syndrome correlation

Finding the link between Guillain-Barré and Takotsubo

Takotsubo cardiomyopathy (‘broken heart syndrome’) is a known complication of Guillain-Barré, but not much is known about the association between the two. New research aims to change this.

Related products

Subscribe to Newsletter